Physician profile
James Appelbaum
NPI 1063426369
$15,223.66
in general payments reported to CMS, 2019-2025
66 companies · $2,712 in 2025
The $2,712 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,504 · 2020: $1,411 · 2021: $1,922 · 2022: $2,224 · 2023: $2,713 · 2024: $2,739 · 2025: $2,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,043 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,042.67 |
| Education | $120.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,327.19 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Abbvie INC. | $1,246.26 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Teva Pharmaceuticals USA, INC. | $1,184.85 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Emd Serono, INC. | $1,176.92 | 2019-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $1,110.98 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $886.80 | 2021-2025 | Ingrezza, Ongentys |
| Amgen INC. | $696.89 | 2019-2022 | |
| Biogen, INC. | $676.17 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Jazz Pharmaceuticals INC. | $597.73 | 2019-2025 | |
| Pfizer INC. | $570.80 | 2020-2025 | |
| Celgene Corporation | $508.46 | 2021-2025 | Zeposia |
| Genzyme Corporation | $417.89 | 2019-2025 | |
| Sk Life Science, INC. | $320.54 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $318.00 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $317.19 | 2023-2025 | Nuplazid |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Appelbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.